Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win

With a likely third place finish in the race to bring a CGRP inhibitor to market for the prevention of migraine headaches, Teva needs something to differentiate its product. Quarterly subcutaneous dosing may help fremanezumab become a fan favorite.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Teva Pharmaceutical Industries Ltd.'s fremanezumab is the third calcitonin gene-related peptide (CGRP) inhibitor to successfully complete a Phase III clinical trial, but two candidates from competing big pharma companies are poised to take first and second place in the race to approval for a blockbuster migraine prevention therapy. That means Teva must exploit a key differentiating feature of its antibody for a potential win in the commercial market.

The company reported on May 31 that both doses of fremanezumab tested in the Phase III HALO CM trial provided...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D